Cyclacel Pharmaceuticals Reports Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Cyclacel Pharma (CYCC) Reports Q2 Loss of $0.10
August 11, 2015 4:45 PM EDTCyclacel Pharma (NASDAQ: CYCC) reported Q2 EPS of ($0.10), versus ($0.22) reported last year. Revenue for the quarter came in at $356 thousand, versus $296 thousand reported last year.
For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.
... More